23 Mar 2009 07:00
| For Immediate Release | 23 March 2009 |
ImmuPharma PLC
Directors' Dealings
Institutions increase stake
ImmuPharma PLC ("ImmuPharma" or the "Company") (LSE:IMM) announces today that a number of existing and new blue-chip institutional investors have purchased shares from the Trusts of two of ImmuPharma's founders and Directors, Richard Warr and Dimitri Dimitriou. The Trusts each placed 2.1 million (2.7 %) ordinary shares of 10 pence each in the Company at a price of 82 pence per share to institutional investors on 19 March.
Following the disposal, the current holdings are:
| Richard Warr (1) | 9,778,968 ordinary shares | (12.6 %) |
| Dimitri Dimitriou (2) | 9,778,969 ordinary shares | (12.6 %) |
(1) Ordinary shares of £0.10 held by Louvre Trustees Limited where the Warr family has a beneficial interest.
(2) Ordinary shares of £0.10 held by Louvre Trustees Limited where the Dimitriou family has a beneficial interest.
Richard Warr, ImmuPharma's Chairman said:
"We are delighted with the demand from new investors, including several blue-chip funds such as Gartmore, Smith & Williamson, Aviva and Rathbones. The allocation of these shares increases ImmuPharma's free float with the aim of improving overall liquidity."
For further information please contact:
| ImmuPharma PLC: | +44 20 7152 4080 |
| Dimitri Dimitriou, Chief Executive Officer | |
| Richard Warr, Chairman | |
| Panmure Gordon | +44 151 243 0963 |
| Andrew Burnett/ Rakesh Sharma (Corporate Finance) | |
| Ashton Clanfield (Corporate Broking) | |
| Buchanan Communications: | +44 20 7466 5000 |
| Lisa Baderoon | |
| Rebecca Skye Dietrich |
More information on the company can be found at www.immupharma.com
Immupharma (IMM)